Cargando...
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells
Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olap...
Gardado en:
| Publicado en: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154848/ https://ncbi.nlm.nih.gov/pubmed/30024813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472189 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|